, Volume 124, Issue 4, pp 355–364 | Cite as

Ethological analysis of cholecystokinin (CCKA and CCKB) receptor ligands in the elevated plus-maze test of anxiety in mice

  • N. J. T. Johnson
  • R. J. Rodgers
Original Investigation


The literature on the effects of CCK receptor manipulations in animal models of anxiety is rife with inconsistency, and the data subject to a variety of methodological and interpretative difficulties. In the present paper, the effects of a range of CCK receptor ligands on anxiety in male mice have been assessed using an ethological version of the elevated plusmaze test. Compounds selected for study were the agonists, CCK-4 and CCK-8s (12.5–100µg/kg), and the antagonists, devazepide, L-365, 260 and PD 135158 (1.0 µg/kg–1.0mg/kg). CCK-4 failed to produce any significant behavioural effects over the dose range tested, while treatment with the sulphated octapeptide, CCK-8s, induced signs of behavioural inhibition at 100 µ/kg without altering anxiety-related indices. Furthermore, in contrast to the clear anxiolytic profile of diazepam (1 mg/kg), and despite the comprehensive behavioural profiles yielded by ethological analysis, all three CCK receptor antagonists studied (devazepide, L-365, 260 and PD 135158) were found to be without significant effect under present test conditions. Together, present findings provide little support for the involvement of CCK receptor mechanisms in anxiety and, in particular, the form of anxiety evoked in mice by exposure to a plus-maze.

Key words

Anxiety Plus-maze Ethological analysis CCK-4 CCK-8s Devazepide L-365, 260 PD135158 Diazepam Mice 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abelson JL, Nesse RM (1994) Pentagastrin infusions in patients with panic disorder. 1.Symptoms and cardiovascular responses. Biol Psychiatry 36:73–83Google Scholar
  2. Adamec RE, Shallow T (1993) Lasting effects on rodent anxiety of a single exposure to a cat. Physiol Behav 54:101–109Google Scholar
  3. Bickerdike MJ, Marsden CA, Dourish CT, Fletcher A (1994) The influence of 5-hydroxytryptamine reuptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze. Eur J Pharmacol 271:403–411Google Scholar
  4. Bradwejn J, Koszycki D, Meterissian G (1990) Cholecystokinintetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry 35:83–85Google Scholar
  5. Bradwejn J, Koszycki D, Shriqui C (1991) Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder — clinical and behavioral findings. Arch Gen Psychiatry 48:603–610Google Scholar
  6. Bradwejn J, Koszycki D, Couetoux du Tertre A, Bourin M, Palmour RM, Ervin FR (1992) The cholecystokinin hypothesis of panic and anxiety disorders: a review. J Psychopharmacol 6:345–351Google Scholar
  7. Bradwejn J, Koszycki D, Dutertre AC Vanmegen H, Denboer J, Westenberg H, Annable L (1994) The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 51:486–493Google Scholar
  8. Chopin P, Briley M (1993) The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze. Psychopharmacology 110:409–414Google Scholar
  9. Cole JC, Rodgers RJ (1993) An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 16-6028) in the murine elevated plus-maze. Behav Pharmacol 4:573–580Google Scholar
  10. Cole JC, Rodgers RJ (1994) Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test — comparison with haloperidol. Psychopharmacology 114:288–296Google Scholar
  11. Cole JC, Rodgers RJ (1995) Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behaviour of mice in the elevated plus-maze. Pharmacol Biochem Behav 52:473–478Google Scholar
  12. Cole, JC, Burroughs, GJ, Laverty, CR, Sherriff, NC, Sparham, EA, Rodgers RJ (1995) Anxiolytic-like effects of yohimbine in the murine plus-maze: strain independence and evidence against α2-adrenoceptor mediation. Psychopharmacology 118:425–436Google Scholar
  13. Costall B, Domeney AM, Hughes J, Kelly ME, Naylor RJ, Woodruff GN (1991) Anxiolytic effects of CCK-B antagonists. Neuropeptides 19:65–73Google Scholar
  14. Crawley JN, Corwin RL (1994) Biological actions of cholecystokinin. Peptides 15:731–755Google Scholar
  15. Cutler NR, Sramek JJ, Kramer MS, Reines SA (1994) Placebo-controlled study of a CCKB antagonist in patents with panic disorder. Biol Psychiatry 35:680Google Scholar
  16. Dauge V, Derrien M, Durieux C, Noble F, Corringer PJ, Roques BP (1992) Effects of selective agonists for cholecystokinin receptors CCK-B in nociception and behavior in rodents. Therapie 47:531–539Google Scholar
  17. Dawson GR, Rupniak NMJ, Iversen SD, Tricklebank MD (1994) Lack of effect of CCKB receptor antagonists in animal screens for anxiolytic drugs. J Psychopharmacol 8:A47Google Scholar
  18. DeMontigny C (1989) Cholecystokinin tetrapeptide induces panic-like attacks in healthy-volunteers — preliminary findings. Arch Gen Psychiatry 46:511–517Google Scholar
  19. Derrien M, Durieux C, Dauge V, Roques BP (1993) Involvement of D(2) dopaminergic receptors in the emotional and motivational responses induced by injection of CCK-8 in the posterior part of the rat nucleus-accumbens. Brain Res 617:181–188Google Scholar
  20. Derrien M, McCort-Tranchepain I, Ducos B, Roques BP, Durieux C (1994) Heterogeneity of CCK-B receptors involved in animal-models of anxiety. Pharmacol Biochem Behav 49:133–141Google Scholar
  21. Dourish CT, Bickerdike MJ, Stanhope KJ, Fletcher A, Marsden CT (1994) Profile of CCKA and CCKB receptor antagonists in the CER end elevated plus-maze models of anxiety in the rat: modulation by 5-HT reuptake blockade. Behav Pharmacol 5:29–30Google Scholar
  22. Ervin FR, Palmour RM, Bradwejn J (1991) A new primate model for panic disorder. Biol Psychiatry 29:430SGoogle Scholar
  23. Fink H, Rex A, Marsden CA (1994) Behavioural and neurochemical effects of CCK-fragments in animal models of anxiety. Behav Pharmacol 5:30Google Scholar
  24. Harro J, Vasar E (1991a) Cholecystokinin-induced anxiety — how is it reflected in studies on exploratory-behavior? Neurosci Biobehav Rev 15:473–477Google Scholar
  25. Harro J, Vasar E (1991b) Evidence that CCKB receptors mediate the regulation of exploratory behavior in the rat. Eur J Pharmacol 193:379–381Google Scholar
  26. Harro J, Pold M, Vasar E (1990) Anxiogenic-like action of cerulein, a CCK-8 receptor agonist, in the mouse-influence of acute and subchronic diazepam treatment. Naunyn-Schmiedeberg's Arch Pharmacol 341:62–67Google Scholar
  27. Harro J, Vasar E, Bradwejn J (1993) CCK in animal and human research on anxiety. Trends Pharmacol Sci 14:244–249Google Scholar
  28. Hays SE, Beinfeld MC, Jensen RT, Goodwin FK, Paul SM (1980) Demonstration of a putative receptor site for cholecystokinin in the rat brain. Neuropeptides 1:53–62Google Scholar
  29. Hendrie CA, Dourish CT (1993) Effects of cholecystokinin tetrapeptide (CCK-4) and the CCKB antagonist LY-288513 in a putative model of panic in the mouse. Br J Pharmacol 108:26PGoogle Scholar
  30. Hendrie CA, Neill JC (1992) Ethological analysis of the role of CCK in anxiety. In: Dourish CT, Cooper SJ, Iversen SD, Iversen LL (eds) Multiple cholecystokinin receptors in the CNS. Oxford University Press, Oxford, pp 132–142Google Scholar
  31. Hughes J, Boden P, Costall B et al. (1990) Development of a class of selective cholecystokinin type-B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 87:6728–6732Google Scholar
  32. Innis RB, Snyder SH (1980) Cholecystokinin receptor binding in brain and pacreas: regulation of pancreatic binding by cyclic and acyclic guanine nucleotides. Eur J Pharmacol 65:123–124Google Scholar
  33. Ivy AC, Goldberg EA (1928) A hormone mechanism for gall bladder contraction and evacuation. Am J Physiol 86:599–613Google Scholar
  34. Jensen RT, Lemp GF, Gardner JD (1980) Interaction of cholecystokinin with specific membrane receptors on pancreatic acinae cells. Proc Natl Acad Sci USA 77:2079–2083Google Scholar
  35. Jorpes JE, Mutt V (1966) Cholecystokinin and pancreozymin, one single hormone? Acta Physiol Scand 66:196–202Google Scholar
  36. Lines C, traub M, Ambrose J (1993) CCK and anxiety in normal volunteers. Neuropsychopharmacology 9:S 181–182Google Scholar
  37. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92:180–185Google Scholar
  38. Mannisto PT, Lang A, Harro J, Peuranen E, Bradwejn J, Vasar E (1994) Opposite effects mediated by CCKA and CCKB receptors in behavioral and hormonal studies in rats. Naunyn-Schmiedeberg's Arch Pharmacol 349:478–484Google Scholar
  39. Moran TH, Robinson PH, Goldrich MS, Mchugh PR (1986) 2 brain cholecystokinin receptors — implications for behavioral actions. Brain Res 362:175–179Google Scholar
  40. Newman JD, Crepeau LJ (1991) Heart rate changes following administration of putative panicogenic chemicals in squirrel monkeys. Soc Neurosci Abstr 17:420.13Google Scholar
  41. Pavlasevic S, Bednar I, Qureshi GA, Sodersten P (1993) Brain cholecystokinin tetrapeptide levels are increased in a rat model of anxiety. Neuroreport 5:225–228Google Scholar
  42. Pellow S, Chopin P, File SE, Briley M (1985) Validation of openclosed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149–169Google Scholar
  43. Rataud J, Darche F, Piot O, Stutzmann JM, Bohme GA, Blanchard JC (1991) Anxiolytic effect of CCK-Antagonists on plus-maze behavior in mice. Brain Res 548:315–317Google Scholar
  44. Ravard S, Dourish CT (1990) Cholecystokinin and anxiety. Trends Pharmacol Sci 11:271–273Google Scholar
  45. Ravard S, Dourish CT, Iversen SD (1990) Evidence that the anxiolytic-like effects of the CCK antagonists devazepide and L-365, 260 in the elevated plus-maze paradigm in rats are mediated by CCK receptors. Br J Pharmacol 101:576PGoogle Scholar
  46. Rehfeld JF (1992) CCK and anxiety: introduction. In: Dourish CT, Cooper SJ, Iversen SD, Iversen LL (eds) Multiple cholecystokinin receptors in the CNS. Oxford University Press, Oxford, pp 117–120Google Scholar
  47. Rex A, Barth T, Voigt JP, Domeney AM, Fink H (1994a) Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin-octapeptide in rat models of anxiety. Neurosci Lett 172:139–142Google Scholar
  48. Rex A, Fink H, Marsden CA (1994b) Effects of BOC-CCK-4 and L365, 260 on cortical 5-HT release in guinea-pigs on exposure to the elevated plus-maze. Neuropharmacology 33:559–565Google Scholar
  49. Rodgers RJ, Cole JC (1993) Anxitey enhancement in the murine elevated plus-maze by immediate prior exposure to social stressors. Physiol Behav 53:83–388Google Scholar
  50. Rodgers RJ, Cole JC (1994a) The elevated plus-maze: pharmacology, methodology and ethology. In: Cooper SJ, Hendrie CA (eds) Ethology and Psychopharmacology. Wiley, Chichester, pp 9–44Google Scholar
  51. Rodgers RJ, Cole JC (1994b) Anxiolytic-like effect of (s)-WAY-100135, a 5-HT1A receptor antagonist, in the murine elevated plus-maze test. Eur J Pharmacol 261:321–325Google Scholar
  52. Rodgers RJ, Johnson NJT (1995a) Cholecystokinin and anxiety: promises and pitfalls. Crit Rev Neurobio (in press)Google Scholar
  53. Rodgers RJ, Johnson NJT (1995b) Factor analysis of the spatiotemporal and ethological measures in the murine elevated plus-maze. Pharmacol Biochem Behav 52:297–303Google Scholar
  54. Rodgers RJ, Shepherd JK (1993) Influence of prior maze experience on behaviour and response to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice. Psychopharmacology 113:237–242Google Scholar
  55. Rodgers RJ, Cole JC, Cobain MR, Daly P, Doran PJ, Eells JR, Wallis P (1992a) Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plus-maze — profile comparisons with 8-OH-DPAT, CGS 12066B, TFMPP and mCPP. Behav Pharmacol 3:621–634Google Scholar
  56. Rodgers RJ, Lee C, Shepherd JK (1992b) Effects of diazepam on behavioural and antinociceptive responses to the elevated plusmaze in male mice depend upon treatment regimen and prior maze experience. Psychopharmacology 106:102–110Google Scholar
  57. Rodgers RJ, Cole JC, Davies A (1994a) Antianxiety and behavioral suppressant actions of the novel 5-HT1A receptor agonist, flesinoxan. Pharmacol Biochem Behav 48:959–963Google Scholar
  58. Rodgers RJ, Nikulina EM, Cole JC (1994b) Dopamine D-1 and D-2 receptor ligands modulate the behavior of mice in the elevated plus-maze. Pharmacol Biochem Behav 49:985–995Google Scholar
  59. Rodgers RJ, Cole JC, Aboualfa K, Stephenson LH (1995) Ethopharmacological analysis of the effects of putative “anxiogenic” agents in the mouse elevated plus-maze. Pharmacol Biochem Behav 52 (in press)Google Scholar
  60. Rupniak NMJ, Schaffer L, Siegl P, Iversen SD (1993) Failure of intravenous pentagastrin challenge to induce panic-like effects in rhesus-monkeys. Neuropeptides 25:115–119Google Scholar
  61. Saito A, Goldfine ID, Williams JA (1980) Characterization of receptors for cholecystokinin and related peptides in mouse cerebral cortex. J Neurochem 37:433–490Google Scholar
  62. Sauter A, Frick W (1983) Determination of cholecystokinin tetrapeptide and cholecystokinin octapeptide sulfate in different rat-brain regions by high-pressure liquid-chromatography with electrochemical detection. Anal Biochem 133:307–313Google Scholar
  63. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT (1994) Behavioral and pharmacological characterization of the elevated zero-maze as an animal-model of anxiety. Psychopharmacology 116:56–64Google Scholar
  64. Singh L, Field MJ, Hughes J, Menzies R, Oles RJ, Vass CA, Woodruff GN (1991a) The behavioral properties of CI-988, a selective cholecystokinin(B) receptor antagonist. Br J Pharmacol 104:239–245Google Scholar
  65. Singh L, Lewis AS, Field MJ, Hughes J, Woodruff GN (1991b) Evidence for an involvement of the brain cholecystokinin-B receptor in anxiety. Proc Natl Acad Sci USA 88:1130–1133Google Scholar
  66. Treit D, Menard J, Royan C (1993) Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav 44:463–469Google Scholar
  67. Vanderhaegen JJ, Signeau JC, Gepts W (1975) New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature 257:604–605Google Scholar
  68. Van Megen HJGM, Westenberg HGM, Denboer JA, Haigh JRM, Traub M (1994) Pentagastrin induced panic attacks — enhanced sensitivity in panic disorder patients. Psychopharmacology 114:449–455Google Scholar
  69. Vasar E, Peuranen E, Harro J, Lang A, Oreland L, Mannisto PT (1993a) Social-isolation of rats increases the density of cholecystokinin receptors in the frontal-cortex and abolishes the antiexploratory effect of cerulein. Naunyn-Schmiedeberg's Arch Pharmacol 348:96–101Google Scholar
  70. Vasar E, Peuranen E, Oopik T, Harro J, Mannisto PT (1993b) Ondansetron, an antagonist of 5-HT3-receptors, antagonizes the antiexploratory effect of cerulein, an agonist of CCK-receptors, in the elevated plus-maze. Psychopharmacology 110:213–218Google Scholar
  71. Vasar E, Lang A, Harro J, Bourin M, Bradwejn J (1994) Evidence for potentiation by CCK antagonists of the effect of cholecystokinin-octapeptide in the elevated plus-maze. Neuropharmacology 33:729–735Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • N. J. T. Johnson
    • 1
  • R. J. Rodgers
    • 1
  1. 1.Ethopharmacology Laboratory, Department of PsychologyUniversity of LeedsLeedsUK

Personalised recommendations